查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药品契约製造市场：按服务（药品市场开拓、药品、生技药品、包装/标籤、填充和精加工）、最终用户、地区划分 - 预测至 2029 年
市场调查报告书
商品编码
1543642

药品契约製造市场：按服务（药品市场开拓、药品、生技药品、包装/标籤、填充和精加工）、最终用户、地区划分 - 预测至 2029 年

Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule, Oral Liquid), Biologics (API, FDF), Packaging & Labelling, Fill-finish), End Users - Global Forecasts to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 385 Pages | 订单完成后即时交付

价格

全球药品契约製造市场规模预计将从 2024 年的 2,009 亿美元增至 2029 年的 3,196 亿美元，2024-2029 年预测期间复合年增长率为 9.7%。

药品契约製造市场的扩张主要是由于对具有成本效益的学名药的需求不断增长以及普通药品专利到期即将到期而推动的。这迫使企业优先考虑关键能力，增加对受託製造服务的需求并加速市场成长。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
考虑单位 金额（十亿美元）
部分 按服务、按最终用户、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲

按服务划分，药品契约製造市场分为药物开发服务、药品製造服务、生技药品製造服务、包装和标籤服务、灌装和加工服务以及其他服务。生技药品製造服务产业预计在 2024-2029 年预测期内将以最高的年复合成长率（CAGR）成长。这种增长可归因于对生技药品和标靶药物治疗的需求增加，以及细胞和基因治疗管道中进行的试验数量的增加。由于这些原因，细分市场的成长可能是正面的。

药品契约製造市场细分包括北美、欧洲、亚太地区、拉丁美洲以及中东和非洲。 2023年，北美将在药物开发和受託製造市场占据压倒性份额。该地区的优势源于多种因素，包括该地区大公司的存在以及持续的药品研发和受託製造。由于个人化药物意识的增强、新兴市场政府对学名药的努力以及合约药物开发和受託製造市场的新参与企业，预计亚太地区的成长步伐将进一步加快。

该报告研究了全球药品契约製造市场，并按服务、最终用户、地区和进入市场的公司概况总结了趋势。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 价格分析
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 技术分析
  • 波特五力分析
  • 监管状况
  • 2024-2025年重大会议和活动
  • 主要相关人员和采购标准
  • 影响客户业务的趋势/干扰
  • 简化新药申请 (ANDA)核准
  • 投资金筹措场景
  • 人工智慧/生成人工智慧对药品契约製造市场的影响

第六章 药品契约製造市场（依服务）

  • 介绍
  • 药品製造服务
  • 药物开发服务
  • 生技药品製造服务
  • 包装和标籤服务
  • 灌装和整理服务
  • 其他服务

第七章 药品契约製造市场（依最终用户）

  • 介绍
  • 大型製药公司
  • 中小型製药企业
  • 学名药公司
  • 其他的

第八章 药品契约製造市场（分地区）

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东
  • 非洲

第9章 竞争格局

  • 介绍
  • 主要参与企业的策略/秘密
  • 收益分析
  • 市场占有率分析
  • 企业评估矩阵：主要参与企业，2023
  • 企业评估矩阵：Start-Ups/小型企业，2023 年
  • 品牌/服务比较
  • 企业价值评估及财务指标
  • 竞争场景

第十章 公司简介

  • 主要参与企业
    • THERMO FISHER SCIENTIFIC INC.
    • LONZA
    • CATALENT, INC.
    • WUXI APPTEC
    • WUXI BIOLOGICS
    • SAMSUNG BIOLOGICS
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • EVONIK INDUSTRIES AG
    • FUJIFILM HOLDINGS CORPORATION
    • ABBVIE INC.
    • SIEGFRIED HOLDING AG
    • MERCK KGAA
    • ALMAC GROUP
    • CHARLES RIVER LABORATORIES
    • ASYMCHEM INC.
    • VETTER PHARMA
    • ALCAMI CORPORATION
  • 其他公司
    • PIRAMAL PHARMA SOLUTIONS
    • SYNGENE INTERNATIONAL LIMITED
    • CAMBREX CORPORATION
    • JUBILANT BIOSYS LTD.
    • YUHAN CORPORATION
    • PIERRE FABRE GROUP
    • PFIZER CENTREONE
    • DELPHARM
    • FRONTAGE LABS
    • SHARP SERVICES, LLC
    • GRAND RIVER ASEPTIC MANUFACTURING

第十一章附录

Product Code: PH 7263

The global pharmaceutical contract manufacturing market is projected to reach USD 319.6 billion by 2029 from USD 200.9 billion in 2024, at a CAGR of 9.7% during the forecast period of 2024 to 2029. The expansion of the pharmaceutical contract manufacturing market has been primarily propelled by the rising need for generic drugs, which are cost-effective, and the approaching expiration of patents for popular medications. This has compelled companies to prioritize their main functions, leading to increased demand for contract manufacturing services and accelerating the growth of the market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Billion)
SegmentsService, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, Africa

"The biologics manufacturing services segment is anticipated to experience the highest compound annual growth rate (CAGR) over the period of forecasting that spans from 2024 to 2029."

Based on service, the drug development services, pharmaceutical manufacturing services, biologics manufacturing services, packaging and labelling services, fill-finish services, and other services segment the pharmaceutical contract manufacturing market. It is anticipated that the biologics manufacturing services segment would grow at the highest compound annual growth rate (CAGR) over the period of forecasting in 2024-2029. The growth can be due to the increasing demand for biologics and targeted pharmacological therapies, as well as the rise in the number of studies that are being conducted in the pipeline for cell and gene therapy. Because of these reasons, there is a good chance that segmental growth will be positively affected.

"The growth of the Asia Pacific pharmaceutical contract manufacturing market is likely to be at faster pace during the period of the forecast from 2024-2029."

The segmentations of the pharmaceutical contract manufacturing market include North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa. In 2023, North America accounted for the dominant share of the pharmaceutical contract development and manufacturing market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of pharmaceutical contract Development and Manufacturing. With increasing awareness about personalized therapeutics, growing initiatives in the region by governments for generics medicines, and the entry of new participants into the pharmaceutical contract development and manufacturing market, the pace of growth in the Asia Pacific region is likely to be faster.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60% and Demand Side 40%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Catalent, Inc. (US)
  • Lonza Group (Switzerland)
  • AbbVie, Inc. (US)
  • WuXi Apptec (China)
  • WuXi Biologics (China)
  • Merck KGaA (Germany)
  • Siegfried Holding AG (Switzerland)
  • Evonik Industries AG (Germany)
  • Boehringer Ingelheim International (Germany)
  • FUJIFILM Holding Corporation (Japan)
  • Samsung Biologics (South Korea)
  • Almac Group (UK)
  • Vetter Pharma (Germany)
  • Alcami Corporation (US)
  • Asychem Inc. (China)
  • Charles River Laboratories (US)
  • Piramal Pharma Solutions (India)
  • Syngene (Biocon Limited) (India)
  • Delpharm Holdings (France)
  • Yuhan Corporation (South Korea)
  • Cambrex Corporation. (US)
  • Sharp Services, LLC (US)
  • Grand River Aseptic Manufacturing (US)
  • Jubilant Biosys Ltd. (India)
  • Pierre Fabre group (France)
  • pfizer centerOne (US)
  • Frontage Labs (US)

Research Coverage:

This research report categorizes the pharmaceutical contract manufacturing market by service (drug development services, pharmaceutical manufacturing services (pharmaceutical API manufacturing services, pharmaceutical FDF manufacturing services (parenteral, tablet, capsule, oral liquid, semi-solid, other formulations), biologics manufacturing services (biologics API manufacturing services, biologics FDF manufacturing services), packaging & labelling services, fill-finish services, other services)), end user (big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, others), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical contract manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, services, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the pharmaceutical contract manufacturing market.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing them with the most accurate estimates of the revenue figures for the entire pharmaceutical contract manufacturing market and its subsegments. Moreover, examining subsegments would improve stakeholders' understanding of the competitive landscape and offer them vital insights to effectively position their company and formulate suitable go-to-market strategies. The objective of this research is to provide stakeholders with a clear understanding of the current market situation. This will be achieved by presenting them with detailed information about the main aspects that impact the industry, such as drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increased investment in precision medicines, Patent expiry & increasing demand for generic drugs, High cost of in-house drug development, Investments in advanced manufacturing technologies by CDMOs), restraints (Varying regulatory requirements across various regions), opportunities (Rising demand for cell & gene therapies, Growing inclination toward one-stop-shop model, Market expansion in emerging countries, Growth of nuclear medicine), and challenges (Introduction of serialization, Intellectual property risk) influencing the growth of pharmaceutical contract development and manufacturing market.
  • Service Development/Innovation: Thorough investigation of lately launched services available in the pharmaceutical contract manufacturing market.
  • Market Development: By means of analysis of regional market trends, the study offers comprehensive knowledge on profitable markets.
  • Market Diversification: Comprehensive information on new services, underdeveloped areas, present developments, and pharmaceutical contract manufacturing sector investments is what markets diversification is based on.
  • Competitive Assessment: A comprehensive evaluation of the market shares, growth strategies, and service offerings of prominent companies such as Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China), and others in the pharmaceutical contract development and manufacturing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.2 INSIGHTS FROM PRIMARY SOURCES
  • 2.3 GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
  • 4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE & COUNTRY, 2023
  • 4.3 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
  • 4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
  • 4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increased investments in precision medicines
      • 5.2.1.2 Rising demand for generic drugs
      • 5.2.1.3 Need for affordable drug development
      • 5.2.1.4 Favorable initiatives by contract development and manufacturing organizations
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent regulatory requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emergence of cell and gene therapies
      • 5.2.3.2 Growing inclination toward one-stop-shop model
      • 5.2.3.3 Growth opportunities in emerging countries
      • 5.2.3.4 Booming nuclear medicine market
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Introduction of serialization
      • 5.2.4.2 Intellectual property risk
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE PRICING ANALYSIS, BY SERVICE
    • 5.3.2 INDICATIVE PRICING ANALYSIS, BY REGION
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    • 5.7.1 KEY TECHNOLOGIES
      • 5.7.1.1 Single-use bioprocessing systems
      • 5.7.1.2 Continuous manufacturing
      • 5.7.1.3 Advanced formulation technologies
    • 5.7.2 COMPLEMENTARY TECHNOLOGIES
      • 5.7.2.1 High-performance liquid chromatography
      • 5.7.2.2 Mass spectrometry
      • 5.7.2.3 Next-generation sequencing
      • 5.7.2.4 Automation and robotics
      • 5.7.2.5 Process analytical technology
    • 5.7.3 ADJACENT TECHNOLOGIES
      • 5.7.3.1 3D printing
      • 5.7.3.2 Artificial intelligence and machine learning
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    • 5.9.1 REGULATORY SCENARIO
    • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.11.2 BUYING CRITERIA
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.13 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET

6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE

  • 6.1 INTRODUCTION
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    • 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
      • 6.2.1.1 Rising cases of patent expiry to fuel market
    • 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
      • 6.2.2.1 Parenteral manufacturing services
        • 6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support market growth
      • 6.2.2.2 Tablet manufacturing services
        • 6.2.2.2.1 Growing domestic production capacity in emerging markets to accelerate growth
      • 6.2.2.3 Capsule manufacturing services
        • 6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth
      • 6.2.2.4 Oral liquid manufacturing services
        • 6.2.2.4.1 Growing preference for oral liquids over powders to facilitate growth
      • 6.2.2.5 Semi-solid manufacturing services
        • 6.2.2.5.1 Rising prevalence of skin infections and burns to propel market
      • 6.2.2.6 Other FDF manufacturing services
  • 6.3 DRUG DEVELOPMENT SERVICES
    • 6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
  • 6.4 BIOLOGICS MANUFACTURING SERVICES
    • 6.4.1 BIOLOGICS API MANUFACTURING SERVICES
      • 6.4.1.1 Expanding offerings in cell line development and production to aid market growth
    • 6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
      • 6.4.2.1 Growing importance due to therapeutic potential to encourage growth
  • 6.5 PACKAGING & LABELING SERVICES
    • 6.5.1 INCREASING STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR MARKET GROWTH
  • 6.6 FILL-FINISH SERVICES
    • 6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO DRIVE MARKET
  • 6.7 OTHER SERVICES

7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER

  • 7.1 INTRODUCTION
  • 7.2 BIG PHARMACEUTICAL COMPANIES
    • 7.2.1 RISING PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO MARKET GROWTH
  • 7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
    • 7.3.1 NEED TO SAVE COSTS ON IN-HOUSE DRUG MANUFACTURING TO BOOST MARKET
  • 7.4 GENERIC PHARMACEUTICAL COMPANIES
    • 7.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
  • 7.5 OTHER END USERS

8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION

  • 8.1 INTRODUCTION
  • 8.2 NORTH AMERICA
    • 8.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 8.2.2 US
      • 8.2.2.1 Presence of major pharmaceutical companies to drive market
    • 8.2.3 CANADA
      • 8.2.3.1 Favorable government support to sustain market growth
  • 8.3 EUROPE
    • 8.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 8.3.2 GERMANY
      • 8.3.2.1 Free drug pricing policy to speed up market growth
    • 8.3.3 UK
      • 8.3.3.1 Favorable R&D funding scenario to augment growth
    • 8.3.4 FRANCE
      • 8.3.4.1 Booming life science research to fuel market
    • 8.3.5 ITALY
      • 8.3.5.1 Rising commercial drug development to favor growth
    • 8.3.6 SWITZERLAND
      • 8.3.6.1 Role as global pharmaceutical manufacturing hub to fuel market
    • 8.3.7 POLAND
      • 8.3.7.1 Universal health coverage and advanced infrastructure to encourage growth
    • 8.3.8 SPAIN
      • 8.3.8.1 Growing outsourcing of development and trial phases to boost market
    • 8.3.9 REST OF EUROPE
  • 8.4 ASIA PACIFIC
    • 8.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 8.4.2 CHINA
      • 8.4.2.1 Made in China 2025 initiative to aid market growth
    • 8.4.3 INDIA
      • 8.4.3.1 Favorable industrial environment and lower labor costs to drive market
    • 8.4.4 AUSTRALIA
      • 8.4.4.1 Strategic geographical location to foster growth
    • 8.4.5 JAPAN
      • 8.4.5.1 Growing geriatric population to augment growth
    • 8.4.6 SOUTH KOREA
      • 8.4.6.1 Initiatives for enhanced workforce, improved regulations, and R&D for new drugs to promote growth
    • 8.4.7 REST OF ASIA PACIFIC
  • 8.5 LATIN AMERICA
    • 8.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 8.5.2 BRAZIL
      • 8.5.2.1 Rapid patient enrolment and presence of highly experienced investigators for clinical trials to expedite growth
    • 8.5.3 MEXICO
      • 8.5.3.1 Surge in pharmaceutical goods export to promote growth
    • 8.5.4 REST OF LATIN AMERICA
  • 8.6 MIDDLE EAST
    • 8.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 8.6.2 GCC COUNTRIES
      • 8.6.2.1 Kingdom of Saudi Arabia
        • 8.6.2.1.1 Growing focus on enhanced healthcare expenditure to aid market growth
      • 8.6.2.2 UAE
        • 8.6.2.2.1 Growing population and healthcare spending to drive market
      • 8.6.2.3 Other GCC Countries
    • 8.6.3 REST OF MIDDLE EAST
  • 8.7 AFRICA
    • 8.7.1 RISING CASES OF CANCER AND OTHER CHRONIC DISEASES TO FACILITATE GROWTH
    • 8.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
  • 9.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 9.3 REVENUE ANALYSIS
  • 9.4 MARKET SHARE ANALYSIS
  • 9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
    • 9.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 9.5.5.1 Company footprint
      • 9.5.5.2 Service footprint
      • 9.5.5.3 End-user footprint
      • 9.5.5.4 Region footprint
  • 9.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 9.6.1 PROGRESSIVE COMPANIES
    • 9.6.2 RESPONSIVE COMPANIES
    • 9.6.3 DYNAMIC COMPANIES
    • 9.6.4 STARTING BLOCKS
    • 9.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 9.7 BRAND/SERVICE COMPARISON
    • 9.7.1 THERMO FISHER SCIENTIFIC INC.
    • 9.7.2 CATALENT, INC.
    • 9.7.3 LONZA
    • 9.7.4 SAMSUNG BIOLOGICS
    • 9.7.5 WUXI APPTEC
  • 9.8 COMPANY VALUATION AND FINANCIAL METRICS
  • 9.9 COMPETITIVE SCENARIO
    • 9.9.1 SERVICE LAUNCHES
    • 9.9.2 DEALS
    • 9.9.3 EXPANSIONS

10 COMPANY PROFILES

  • 10.1 KEY PLAYERS
    • 10.1.1 THERMO FISHER SCIENTIFIC INC.
      • 10.1.1.1 Business overview
      • 10.1.1.2 Services offered
      • 10.1.1.3 Recent developments
        • 10.1.1.3.1 Service launches
        • 10.1.1.3.2 Deals
        • 10.1.1.3.3 Expansions
      • 10.1.1.4 MnM view
        • 10.1.1.4.1 Key strengths
        • 10.1.1.4.2 Strategic choices
        • 10.1.1.4.3 Weaknesses and competitive threats
    • 10.1.2 LONZA
      • 10.1.2.1 Business overview
      • 10.1.2.2 Services offered
      • 10.1.2.3 Recent developments
        • 10.1.2.3.1 Deals
      • 10.1.2.4 MnM view
        • 10.1.2.4.1 Key strengths
        • 10.1.2.4.2 Strategic choices
        • 10.1.2.4.3 Weaknesses and competitive threats
    • 10.1.3 CATALENT, INC.
      • 10.1.3.1 Business overview
      • 10.1.3.2 Services offered
      • 10.1.3.3 Recent developments
        • 10.1.3.3.1 Service launches
        • 10.1.3.3.2 Deals
        • 10.1.3.3.3 Expansions
      • 10.1.3.4 MnM view
        • 10.1.3.4.1 Key strengths
        • 10.1.3.4.2 Strategic choices
        • 10.1.3.4.3 Weaknesses and competitive threats
    • 10.1.4 WUXI APPTEC
      • 10.1.4.1 Business overview
      • 10.1.4.2 Services offered
      • 10.1.4.3 Recent developments
        • 10.1.4.3.1 Deals
        • 10.1.4.3.2 Expansions
      • 10.1.4.4 MnM view
        • 10.1.4.4.1 Key strengths
        • 10.1.4.4.2 Strategic choices
        • 10.1.4.4.3 Weaknesses and competitive threats
    • 10.1.5 WUXI BIOLOGICS
      • 10.1.5.1 Business overview
      • 10.1.5.2 Services offered
      • 10.1.5.3 Recent developments
        • 10.1.5.3.1 Deals
        • 10.1.5.3.2 Expansions
    • 10.1.6 SAMSUNG BIOLOGICS
      • 10.1.6.1 Business overview
      • 10.1.6.2 Services offered
      • 10.1.6.3 Recent developments
        • 10.1.6.3.1 Deals
        • 10.1.6.3.2 Expansions
    • 10.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 10.1.7.1 Business overview
      • 10.1.7.2 Services offered
      • 10.1.7.3 Recent developments
        • 10.1.7.3.1 Deals
        • 10.1.7.3.2 Expansions
    • 10.1.8 EVONIK INDUSTRIES AG
      • 10.1.8.1 Business overview
      • 10.1.8.2 Services offered
      • 10.1.8.3 Recent developments
        • 10.1.8.3.1 Deals
        • 10.1.8.3.2 Expansions
    • 10.1.9 FUJIFILM HOLDINGS CORPORATION
      • 10.1.9.1 Business overview
      • 10.1.9.2 Services offered
      • 10.1.9.3 Recent developments
        • 10.1.9.3.1 Deals
        • 10.1.9.3.2 Expansions
    • 10.1.10 ABBVIE INC.
      • 10.1.10.1 Business overview
      • 10.1.10.2 Services offered
      • 10.1.10.3 Recent developments
        • 10.1.10.3.1 Deals
        • 10.1.10.3.2 Expansions
    • 10.1.11 SIEGFRIED HOLDING AG
      • 10.1.11.1 Business overview
      • 10.1.11.2 Services offered
      • 10.1.11.3 Recent developments
        • 10.1.11.3.1 Deals
        • 10.1.11.3.2 Expansions
    • 10.1.12 MERCK KGAA
      • 10.1.12.1 Business overview
      • 10.1.12.2 Services offered
      • 10.1.12.3 Recent developments
        • 10.1.12.3.1 Deals
        • 10.1.12.3.2 Expansions
    • 10.1.13 ALMAC GROUP
      • 10.1.13.1 Business overview
      • 10.1.13.2 Services offered
      • 10.1.13.3 Recent developments
        • 10.1.13.3.1 Deals
        • 10.1.13.3.2 Expansions
    • 10.1.14 CHARLES RIVER LABORATORIES
      • 10.1.14.1 Business overview
      • 10.1.14.2 Services offered
      • 10.1.14.3 Recent developments
        • 10.1.14.3.1 Deals
        • 10.1.14.3.2 Expansions
    • 10.1.15 ASYMCHEM INC.
      • 10.1.15.1 Business overview
      • 10.1.15.2 Services offered
      • 10.1.15.3 Recent developments
        • 10.1.15.3.1 Deals
        • 10.1.15.3.2 Expansions
    • 10.1.16 VETTER PHARMA
      • 10.1.16.1 Business overview
      • 10.1.16.2 Services offered
      • 10.1.16.3 Recent developments
        • 10.1.16.3.1 Deals
        • 10.1.16.3.2 Expansions
    • 10.1.17 ALCAMI CORPORATION
      • 10.1.17.1 Business overview
      • 10.1.17.2 Services offered
      • 10.1.17.3 Recent developments
        • 10.1.17.3.1 Deals
        • 10.1.17.3.2 Expansions
  • 10.2 OTHER PLAYERS
    • 10.2.1 PIRAMAL PHARMA SOLUTIONS
    • 10.2.2 SYNGENE INTERNATIONAL LIMITED
    • 10.2.3 CAMBREX CORPORATION
    • 10.2.4 JUBILANT BIOSYS LTD.
    • 10.2.5 YUHAN CORPORATION
    • 10.2.6 PIERRE FABRE GROUP
    • 10.2.7 PFIZER CENTREONE
    • 10.2.8 DELPHARM
    • 10.2.9 FRONTAGE LABS
    • 10.2.10 SHARP SERVICES, LLC
    • 10.2.11 GRAND RIVER ASEPTIC MANUFACTURING

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 4 IMPENDING PATENT EXPIRY OF DRUGS, BY YEAR
  • TABLE 5 EXPANSIONS BY TOP COMPANIES, 2022-2024
  • TABLE 6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN SUPPLY CHAIN
  • TABLE 7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 9 REGULATORY SCENARIO, BY COUNTRY
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
  • TABLE 18 BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING, BY END USER
  • TABLE 19 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 20 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 21 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 22 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 23 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 24 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 25 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 26 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 27 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 28 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 29 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 30 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 31 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 32 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 33 MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 34 GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 35 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 36 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 37 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 38 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 39 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 40 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 41 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 42 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 43 PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 44 NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 45 EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 46 ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 47 LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 48 MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 49 GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 50 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 51 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 52 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 53 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 54 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 55 MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 56 GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 57 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 58 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 59 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 60 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 61 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 62 MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 63 GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 64 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 65 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 66 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 67 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 68 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 69 MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 70 GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 71 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 72 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 73 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 74 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 75 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 76 MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 77 GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 78 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 79 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 80 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 81 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 82 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 83 MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 84 GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 85 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 86 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 87 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 88 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 89 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 90 MIDDLE EAST: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 91 GCC COUNTRIES: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 92 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 93 BIOLOGICS MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 94 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 95 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 96 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 97 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 98 MIDDLE EAST: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 99 GCC COUNTRIES: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 100 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 101 NORTH AMERICA: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 102 EUROPE: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 103 ASIA PACIFIC: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 104 LATIN AMERICA: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 105 MIDDLE EAST: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 106 GCC COUNTRIES: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 107 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 108 NORTH AMERICA: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 109 EUROPE: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 110 ASIA PACIFIC: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 111 LATIN AMERICA: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 112 MIDDLE EAST: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 113 GCC COUNTRIES: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 114 PACKAGING & LABELING SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 115 NORTH AMERICA: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 116 EUROPE: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 117 ASIA PACIFIC: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 118 LATIN AMERICA: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 119 MIDDLE EAST: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 120 GCC COUNTRIES: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 121 FILL-FINISH SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 122 NORTH AMERICA: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 123 EUROPE: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 124 ASIA PACIFIC: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 125 LATIN AMERICA: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 126 MIDDLE EAST: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 127 GCC COUNTRIES: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 128 OTHER SERVICES MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 129 NORTH AMERICA: OTHER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 130 EUROPE: OTHER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 131 ASIA PACIFIC: OTHER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 132 LATIN AMERICA: OTHER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 133 MIDDLE EAST: OTHER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 134 GCC COUNTRIES: OTHER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 135 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 136 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 137 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 138 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 139 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 140 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 141 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 142 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 143 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 144 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 145 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 146 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 147 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 148 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 149 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 150 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 151 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 152 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 153 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 154 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 155 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 156 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 157 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 158 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 159 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 160 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 161 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 162 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 163 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 164 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2022-2029 (USD BILLION)
  • TABLE 165 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 166 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 167 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 168 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 169 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 170 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 171 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 172 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 173 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 174 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 175 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 176 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 177 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 178 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 179 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 180 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 181 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 182 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 183 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 184 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 185 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 186 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 187 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 188 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 189 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 190 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 191 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 192 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 193 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 194 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 195 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 196 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 197 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 198 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 199 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 200 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 201 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 202 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 203 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 204 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 205 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 206 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 207 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 208 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 209 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 210 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 211 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 212 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 213 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 214 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 215 POLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 216 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 217 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 218 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 219 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 220 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 221 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 222 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 223 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 224 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 225 REST OF EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 226 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 227 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 228 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 229 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 230 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 231 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 232 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 233 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 234 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 235 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 236 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 237 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 238 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 239 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 240 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 241 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 242 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 243 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 244 AUSTRALIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 245 AUSTRALIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 246 AUSTRALIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 247 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 248 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 249 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 250 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 251 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 252 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 253 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 254 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 255 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 256 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 257 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 258 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 259 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 260 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 261 REST OF ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 262 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 263 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • TABLE 264 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 265 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 266 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 267 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 268 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 269 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 270 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 271 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 272 BRAZIL: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 273 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 274 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 275 MEXICO: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 276 MEXICO: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 277 MEXICO: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 278 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 279 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 280 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 281 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 282 REST OF LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 283 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 284 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 285 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 286 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 287 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 288 MIDDLE EAST: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 289 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 290 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 291 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 292 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 293 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 294 GCC COUNTRIES: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 295 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 296 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 297 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 298 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 299 KINGDOM OF SAUDI ARABIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 300 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 301 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 302 UAE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 303 UAE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 304 UAE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 305 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 306 OTHER GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 307 OTHER GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 308 OTHER GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 309 OTHER GCC COUNTRIES: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 310 OTHER GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 311 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 312 REST OF MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 313 REST OF MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 314 REST OF MIDDLE EAST: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 315 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 316 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022-2029 (USD BILLION)
  • TABLE 317 AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 318 AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 319 AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • TABLE 320 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022-2029 (USD BILLION)
  • TABLE 321 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • TABLE 322 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
  • TABLE 323 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE FOOTPRINT
  • TABLE 324 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: END-USER FOOTPRINT
  • TABLE 325 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT
  • TABLE 326 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 327 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 328 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2021-JULY 2024
  • TABLE 329 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2021-JULY 2024
  • TABLE 330 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 331 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 332 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 333 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021-JULY 2024
  • TABLE 334 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 335 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 336 LONZA: COMPANY OVERVIEW
  • TABLE 337 LONZA: SERVICES OFFERED
  • TABLE 338 LONZA: DEALS, JANUARY 2021-JULY 2024
  • TABLE 339 LONZA: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 340 CATALENT, INC.: COMPANY OVERVIEW
  • TABLE 341 CATALENT, INC.: SERVICES OFFERED
  • TABLE 342 CATALENT, INC.: SERVICE LAUNCHES, JANUARY 2021-JULY 2024
  • TABLE 343 CATALENT, INC.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 344 CATALENT, INC.: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 345 WUXI APPTEC: COMPANY OVERVIEW
  • TABLE 346 WUXI APPTEC: SERVICES OFFERED
  • TABLE 347 WUXI APPTEC: DEALS, JANUARY 2021-JULY 2024
  • TABLE 348 WUXI APPTEC: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 349 WUXI BIOLOGICS: COMPANY OVERVIEW
  • TABLE 350 WUXI BIOLOGICS: SERVICES OFFERED
  • TABLE 351 WUXI BIOLOGICS: DEALS, JANUARY 2021-JULY 2024
  • TABLE 352 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 353 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
  • TABLE 354 SAMSUNG BIOLOGICS: SERVICES OFFERED
  • TABLE 355 SAMSUNG BIOLOGICS: DEALS, JANUARY 2021-JULY 2024
  • TABLE 356 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 357 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 358 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED
  • TABLE 359 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021-JULY 2024
  • TABLE 360 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 361 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
  • TABLE 362 EVONIK INDUSTRIES AG: SERVICES OFFERED
  • TABLE 363 EVONIK INDUSTRIES AG: DEALS, JANUARY 2021-JULY 2024
  • TABLE 364 EVONIK INDUSTRIES AG: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 365 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 366 FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED
  • TABLE 367 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2021-JULY 2024
  • TABLE 368 FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 369 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 370 ABBVIE INC.: SERVICES OFFERED
  • TABLE 371 ABBVIE INC.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 372 ABBVIE INC.: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 373 SIEGFRIED HOLDING AG: COMPANY OVERVIEW
  • TABLE 374 SIEGFRIED HOLDING AG: SERVICES OFFERED
  • TABLE 375 SIEGFRIED HOLDING AG: DEALS, JANUARY 2021-JULY 2024
  • TABLE 376 SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 377 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 378 MERCK KGAA: SERVICES OFFERED
  • TABLE 379 MERCK KGAA: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 380 MERCK KGAA: EXPANSIONS, JANUARY 2021-JUNE 2024
  • TABLE 381 ALMAC GROUP: COMPANY OVERVIEW
  • TABLE 382 ALMAC GROUP: SERVICES OFFERED
  • TABLE 383 ALMAC GROUP: DEALS, JANUARY 2021-JULY 2024
  • TABLE 384 ALMAC GROUP: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 385 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 386 CHARLES RIVER LABORATORIES: SERVICES OFFERED
  • TABLE 387 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021-JULY 2024
  • TABLE 388 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 389 ASYMCHEM INC.: COMPANY OVERVIEW
  • TABLE 390 ASYMCHEM INC.: SERVICES OFFERED
  • TABLE 391 ASYMCHEM INC.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 392 ASYMCHEM INC.: EXPANSIONS, JANUARY 2021-JUNE 2024
  • TABLE 393 VETTER PHARMA: COMPANY OVERVIEW
  • TABLE 394 VETTER PHARMA: SERVICES OFFERED
  • TABLE 395 VETTER PHARMA: DEALS, JANUARY 2021-JULY 2024
  • TABLE 396 VETTER PHARMA: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 397 ALCAMI CORPORATION: COMPANY OVERVIEW
  • TABLE 398 ALCAMI CORPORATION: SERVICES OFFERED
  • TABLE 399 ALCAMI CORPORATION: DEALS, JANUARY 2021-JULY 2024
  • TABLE 400 ALCAMI CORPORATION: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 401 PIRAMAL PHARMA SOLUTIONS: COMPANY OVERVIEW
  • TABLE 402 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
  • TABLE 403 CAMBREX CORPORATION: COMPANY OVERVIEW
  • TABLE 404 JUBILANT BIOSYS LTD.: COMPANY OVERVIEW
  • TABLE 405 YUHAN CORPORATION: COMPANY OVERVIEW
  • TABLE 406 PIERRE FABRE GROUP: COMPANY OVERVIEW
  • TABLE 407 PFIZER CENTREONE: COMPANY OVERVIEW
  • TABLE 408 DELPHARM: COMPANY OVERVIEW
  • TABLE 409 FRONTAGE LABS: COMPANY OVERVIEW
  • TABLE 410 SHARP SERVICES, LLC: COMPANY OVERVIEW
  • TABLE 411 GRAND RIVER ASEPTIC MANUFACTURING: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
  • FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2023
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS, 2024-2029
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2024 VS. 2029 (USD BILLION)
  • FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
  • FIGURE 13 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
  • FIGURE 14 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
  • FIGURE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2024-2029
  • FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
  • FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 18 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 19 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 20 CHINA TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 21 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 AVERAGE COST OF DEVELOPING COMPOUNDS FOR BIOPHARMA COMPANIES, 2013-2023 (USD BILLION)
  • FIGURE 23 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 25 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES
  • FIGURE 28 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 29 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 30 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2019-2023
  • FIGURE 31 REGIONAL BREAKDOWN OF ANDA (ABBREVIATED NEW DRUG APPLICATION) APPROVALS IN 2023
  • FIGURE 32 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS FOR DOSAGE FORMS IN 2023
  • FIGURE 33 INVESTMENT AND FUNDING SCENARIO (2023-2024)
  • FIGURE 34 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • FIGURE 35 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2019-2023 (USD BILLION)
  • FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY KEY PLAYER, 2023
  • FIGURE 39 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 40 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
  • FIGURE 41 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 42 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 LONZA: COMPANY SNAPSHOT (2023)
  • FIGURE 47 CATALENT, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 WUXI APPTEC: COMPANY SNAPSHOT (2023)
  • FIGURE 49 WUXI BIOLOGICS: COMPANY SNAPSHOT (2023)
  • FIGURE 50 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2023)
  • FIGURE 51 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2023)
  • FIGURE 52 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2023)
  • FIGURE 53 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 54 ABBVIE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2023)
  • FIGURE 56 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 57 ASYMCHEM INC.: COMPANY SNAPSHOT (2023)